The weighted-average common shares outstanding are as follows:


	Three Months Ended March 31,
	2024			2023

Numerator:
Net loss	$	(11,571	)	$	(5,037	)
Accretion of financing fees		(144	)		-
Accrued dividends on Series C Preferred Stock		(4,237	)		-
Net loss available to common stockholders - basic	$	(15,952	)	$	(5,037	)
Net loss available to common stockholders - diluted	$	(15,952	)	$	(5,037	)
Denominator:
Weighted average common shares outstanding		17,128,417			16,792,292
Issuance of Warrants		12,451,765			9,753,171
Weighted average common shares outstanding - basic		29,580,182			26,545,463
Weighted average common shares outstanding - diluted		29,580,182			26,545,463

The Company computes earnings per share using the two-class method, which is an earnings allocation formula that determines earnings per share for Common Stock and participating securities. The Company’s participating securities are its grants of restricted stock which contain non-forfeitable rights to dividends. The Company allocates earnings between both classes; however, in periods of undistributed losses, they are only allocated to common shares as the unvested restricted stockholders do not contractually participate in losses of the Company. The Company computes basic earnings per share by dividing net income allocated to common shareholders by the weighted average number of shares outstanding during the period. Warrants issued in connection with the Company's long-term debt were issued at a nominal exercise price and are considered outstanding at the date of issuance. The 2023 Warrant was issued out-of-the money and the Company will apply the treasury stock method to the 2023 Warrant when computing earnings per share. Diluted earnings per share is calculated to give effect to all potentially dilutive common shares that were outstanding during the period. Weighted average diluted common shares outstanding include the incremental shares that would be issued upon the assumed exercise of stock options and the assumed vesting of nonvested share awards. For the three months ended March 31, 2024 and 2023, 4,781,274 and 2,086,898 shares, respectively, were not included in the weighted average common shares outstanding calculation as they were anti-dilutive.